SCHEMBL9905368

SCHEMBL9905368

Cc1noc2cccc(Oc3ccc([N+](=O)[O-])cc3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
HTT P42858 3/20 0.44
HSPB1 P04792 3/20 0.43
ALDH1A1 P00352 5/20 0.41
ATM Q13315 1/20 0.40
PIK3C3 Q8NEB9 1/20 0.39
EDNRB P24530 2/20 0.39
EDNRA P25101 2/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 4/20 0.38
THRB P10828 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
CYP3A4 P08684 2/20 0.37
MAPK1 P28482 2/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904473 0.84 HTT (0.46) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL17188965 0.83 HSPB1 (0.49) MEN1KMT2AHTTHSPB1ALDH1A1
SCHEMBL3484963 0.82 KMT2A (0.53) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL20818065 0.72 MEN1 (0.51) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL27716602 0.72 HTT (0.50) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL7632959 0.72 HSPB1 (0.66) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL1979596 0.72 HSPB1 (0.53) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL4378038 0.71 HSPB1 (0.56) MEN1KMT2ARXFP1HTTHSPB1
SCHEMBL6886413 0.71 KCNA5 (0.48) MEN1KMT2AALDH1A1EDNRAKDM4E
SCHEMBL9923864 0.70 TAS2R8 (0.40) MEN1KMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RXFP1 1961/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RXFP1 1961/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RXFP1 1961/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RXFP1 1961/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MEN1 1367/4885KMT2A 450/4885RXFP1 1686/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RXFP1 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.